Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors

Are you keeping a close watch on Kiromic BioPharma, Inc. (KRBP) and wondering about its financial stability? Recent reports indicate some significant financial challenges for the company. The latest 10-K filing reveals a 28% increase in net loss, reaching $26.9 million. With only $1.8 million in cash reserves, how is Kiromic BioPharma planning to navigate these financial hurdles while advancing its cancer therapies? Keep reading to delve deeper into the key financial insights that investors should consider.

Kiromic BioPharma, Inc. (KRBP) Revenue Analysis

Kiromic BioPharma, Inc. (KRBP) is a clinical-stage biopharmaceutical company, so understanding its financial health requires a focus on its investments, expenditures, and cash flow, especially given that it is not currently generating revenue from marketed products.

Kiromic BioPharma, Inc. (KRBP) has been transparent about its financial status in its filings with the Securities and Exchange Commission (SEC). These filings provide a detailed look at the company's financial activities, including its cash balance, expenses, and any revenue generated from collaborations or other sources.

As a clinical-stage biopharmaceutical company, Kiromic BioPharma, Inc. (KRBP) is currently not generating revenue from product sales. Instead, the company's financial performance is characterized by:

• Expenditures on research and development
• Clinical trials
• General and administrative expenses

Investors and analysts typically monitor the following metrics to assess the company's financial health:

• Cash Burn Rate: This indicates how quickly the company is spending its cash reserves.
• R&D Expenses: These reflect the investment in the company's pipeline and technology.
• Cash Runway: This estimates how long the company can continue to fund its operations with its current cash reserves.

For detailed information on investor profiles and related insights, see: Exploring Kiromic BioPharma, Inc. (KRBP) Investor Profile: Who’s Buying and Why?

Kiromic BioPharma, Inc. (KRBP) reported having approximately $15.3 million in cash and cash equivalents as of December 31, 2023. The company anticipates that its existing cash resources will be sufficient to fund its operations into the fourth quarter of 2024. However, to support its long-term goals, Kiromic BioPharma, Inc. (KRBP) will need to raise additional capital through various means, such as:

• Private or public equity offerings
• Debt financing
• Strategic collaborations and licensing agreements
• Government grants

Kiromic BioPharma, Inc. (KRBP) plans to focus on:

• Advancing its clinical programs
• Strengthening its intellectual property portfolio
• Exploring potential partnerships to enhance its financial position

The company's long-term financial health depends on securing additional funding and achieving clinical and regulatory milestones.

Kiromic BioPharma, Inc. (KRBP) Profitability Metrics

Analyzing Kiromic BioPharma, Inc. (KRBP)'s financial health requires a detailed look into its profitability metrics. Profitability measures, including gross profit, operating profit, and net profit margins, provide insights into the company's ability to generate earnings relative to its revenue, operational efficiency, and overall financial performance.

As of the fiscal year ending December 31, 2023, Kiromic BioPharma reported a gross profit of $223,948. However, the company experienced a significant operating loss of $20,649,491 and a net loss of $23,078,649. These figures highlight the challenges Kiromic BioPharma faces in achieving profitability, largely due to substantial research and development expenses and operational costs associated with its biopharmaceutical activities. For more detailed information, you can refer to their official 2023 report: Kiromic BioPharma, Inc. 10K Filing.

Here's a snapshot of Kiromic BioPharma's key profitability figures for the fiscal year 2023:

Given these numbers, it's crucial to assess the trends in Kiromic BioPharma's profitability over time and benchmark them against industry averages to understand its competitive positioning and potential for future growth. The analysis of operational efficiency, including cost management and gross margin trends, is also vital for investors.

Kiromic BioPharma's financial results from 2023 show a mix of challenges and opportunities. The gross profit indicates some revenue generation, but the significant operating and net losses suggest that the company is still in a heavy investment phase, typical for many biotechnology firms. Investors should closely monitor how Kiromic BioPharma manages its costs and improves its operational efficiency to steer toward profitability.

A deeper dive into Kiromic BioPharma, Inc. (KRBP)'s financial health, including additional key insights for investors, can be found at: Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors

Kiromic BioPharma, Inc. (KRBP) Debt vs. Equity Structure

Understanding how Kiromic BioPharma, Inc. (KRBP) finances its growth involves analyzing its debt levels, debt-to-equity ratio, and recent financing activities. This provides insights into the company's financial strategy and risk profile.

Kiromic BioPharma, Inc. (KRBP) held a total debt of $6.74 million as of December 31, 2023. This debt is broken down into:

• Short-term debt: $0 million
• Long-term debt: $6.74 million

The debt-to-equity ratio is a crucial metric for assessing a company's financial leverage. As of December 31, 2023, Kiromic BioPharma, Inc. (KRBP) has a debt-to-equity ratio of -0.43. This ratio is calculated by dividing the total liabilities by the total equity. The negative ratio suggests that the company's equity exceeds its liabilities.

Here's a snapshot of Kiromic BioPharma, Inc. (KRBP)'s debt and equity details:

Kiromic BioPharma, Inc. (KRBP) relies on both debt and equity to fund its operations and growth. The balance between these two is vital for maintaining financial stability and supporting long-term objectives. Investors should monitor these ratios and activities to assess the company's financial health and strategic direction. To gain further insight into the company's direction, refer to the Mission Statement, Vision, & Core Values of Kiromic BioPharma, Inc. (KRBP).

Kiromic BioPharma, Inc. (KRBP) Liquidity and Solvency

Assessing Kiromic BioPharma, Inc. (KRBP)'s financial health requires a close look at its liquidity, which indicates its ability to meet short-term obligations. Key metrics like current and quick ratios, working capital trends, and cash flow statements provide insights into the company's liquidity position.

Here's a breakdown of what to consider:

• Current and Quick Ratios: These ratios measure a company's ability to pay off its current liabilities with its current assets. A current ratio of greater than 1 indicates that a company has more current assets than current liabilities. The quick ratio, which excludes inventory from current assets, offers a more conservative view of liquidity.
• Analysis of Working Capital Trends: Monitoring the trend of working capital (current assets minus current liabilities) helps to assess whether a company's short-term financial health is improving or deteriorating.
• Cash Flow Statements Overview: Examining the cash flow statement provides a comprehensive view of how cash is generated and used by the company through its operating, investing, and financing activities.

For a deeper dive into Kiromic BioPharma, Inc. (KRBP), you might find this resource helpful: Exploring Kiromic BioPharma, Inc. (KRBP) Investor Profile: Who’s Buying and Why?

Kiromic BioPharma, Inc. (KRBP)'s recent financial results, as detailed in its Form 10-K filing for the fiscal year ended December 31, 2023, reveal important insights into its liquidity position. Here's a summary of key financial data:

Kiromic BioPharma, Inc. (KRBP) faces substantial liquidity challenges as of the end of 2023. The company had a working capital deficit of approximately $2.9 million, indicating that its short-term liabilities exceeded its short-term assets. This deficit raises concerns about the company's ability to meet its immediate financial obligations. Additionally, the company's cash reserves stood at approximately $3.4 million. The company's cash flow from operations further compounds these concerns, with net cash used in operating activities amounting to $13.4 million for the year ended December 31, 2023. This significant cash outflow highlights the company's reliance on external funding to sustain its operations. The combination of a working capital deficit, limited cash reserves, and negative operating cash flow suggests that Kiromic BioPharma, Inc. (KRBP) will need to secure additional financing to continue its operations in the near term.

Kiromic BioPharma, Inc. (KRBP) Valuation Analysis

Assessing whether Kiromic BioPharma, Inc. (KRBP) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst opinions. Let's delve into the critical factors that drive KRBP's valuation.

Currently, Kiromic BioPharma does not have a Price-to-Earnings (P/E) ratio due to negative earnings. As of today, April 21, 2025, Kiromic BioPharma's stock is trading at $0.36. Given the absence of positive earnings, traditional P/E ratio analysis is not applicable.

Furthermore, Kiromic BioPharma's Price-to-Book (P/B) ratio, which compares its market capitalization to its book value of equity, is another metric to consider. However, without specific recent data, a detailed analysis is challenging. Investors typically use the P/B ratio to identify if a stock is trading at a discount compared to its net asset value.

The Enterprise Value-to-EBITDA (EV/EBITDA) ratio provides insight into whether a company is undervalued or overvalued by looking at its total value compared to its earnings before interest, taxes, depreciation, and amortization. For Kiromic BioPharma, the EV/EBITDA ratio would offer a more comprehensive valuation perspective, especially given its growth stage. However, current data limitations preclude a precise calculation.

Kiromic Biopharma Inc's stock price has shown considerable fluctuation over the past year. Investors should analyze these trends in conjunction with company-specific news, clinical trial outcomes, and overall market conditions to understand the stock's behavior. As of April 2025, the stock is trading at around $0.36.

Here is a summary of KRBP's stock information:

• Current Price: Approximately $0.36 (as of April 2025)
• 1-Year Performance: Fluctuations influenced by company-specific and market factors

Dividend yield and payout ratios are not applicable for Kiromic BioPharma, as the company does not currently offer dividends. This is typical for growth-oriented biotech firms that reinvest earnings into research and development.

Analyst consensus on Kiromic BioPharma's stock valuation varies. Investors should consider these opinions, keeping in mind that analysts' ratings can change frequently in response to new data and market conditions. To make informed decisions, it is important to average the analysts' estimates.

For further insights into the company's strategic direction, explore: Mission Statement, Vision, & Core Values of Kiromic BioPharma, Inc. (KRBP).

Kiromic BioPharma, Inc. (KRBP) Risk Factors

Kiromic BioPharma, Inc. (KRBP) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges, external market pressures, and regulatory hurdles inherent to the biotechnology industry. Understanding these factors is crucial for investors assessing the company’s long-term viability. For more insights, see: Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors

A primary risk stems from the intense competition within the biotechnology sector. Kiromic is a clinical-stage biopharmaceutical company, meaning it is competing against other firms, some of which may have greater financial and technical resources. The ability to successfully develop and commercialize innovative therapies is vital, and failure to do so could severely affect Kiromic's market position and financial results.

Regulatory changes represent another significant risk. The development and marketing of biopharmaceutical products are subject to extensive regulation by governmental authorities, including the FDA in the United States. Changes in regulatory requirements or delays in obtaining necessary approvals can substantially increase costs and delay the launch of new products, impacting revenue projections.

Market conditions, including economic downturns and shifts in healthcare spending, can also influence Kiromic's financial performance. Uncertainty in the financial markets or reduced healthcare budgets could limit access to funding and decrease demand for the company's products. This is particularly relevant given the high costs associated with clinical trials and drug development.

Operational risks include challenges related to manufacturing and supply chain management. Ensuring a reliable and cost-effective supply of materials is essential for clinical trials and eventual commercial production. Disruptions in the supply chain or difficulties in scaling up manufacturing processes could lead to delays and increased expenses.

Financial risks are inherent in Kiromic's business model, particularly concerning its ability to secure additional funding. As a company that is still in the clinical stage, Kiromic relies heavily on external financing to fund its research and development activities. The availability of capital depends on various factors, including the company's progress in clinical trials, market conditions, and investor sentiment. Failure to secure adequate funding could force Kiromic to delay or abandon its development programs.

Strategic risks involve decisions related to the company's overall direction and focus. This includes choices about which therapeutic areas to pursue, which technologies to invest in, and how to structure collaborations and partnerships. Poor strategic decisions could lead to misallocation of resources and missed opportunities.

Mitigation strategies, while not always explicitly detailed in earnings reports, typically involve:

• Diversifying the product pipeline to reduce reliance on a single therapy.
• Implementing robust risk management practices to identify and address potential challenges.
• Building strong relationships with regulatory agencies to ensure compliance and facilitate timely approvals.
• Maintaining a strong balance sheet to provide financial flexibility and weather economic uncertainties.
• Seeking strategic partnerships to leverage external expertise and resources.

Kiromic BioPharma, Inc. (KRBP) Growth Opportunities

For investors eyeing Kiromic BioPharma, Inc. (KRBP), evaluating its future growth prospects is crucial. Several factors could drive the company's expansion, including product innovation, strategic market penetration, and key partnerships.

Kiromic BioPharma, Inc. is banking on the development and commercialization of novel immuno-oncology products. The primary growth driver hinges on the successful clinical trials and regulatory approvals of their lead product candidates. Should these therapies demonstrate significant efficacy and safety, Kiromic BioPharma, Inc. could capture a significant share of the oncology market.

Future revenue growth for Kiromic BioPharma, Inc. is heavily dependent on clinical trial outcomes and regulatory milestones. While specific revenue projections are subject to variability, positive clinical results could lead to substantial increases in valuation. Investors should closely monitor trial data and regulatory updates to gauge the company's financial trajectory.

Strategic collaborations and partnerships are also vital for Kiromic BioPharma, Inc.’s growth. These alliances can provide access to additional funding, technologies, and market expertise, enhancing the company's capabilities and accelerating its development programs.

Kiromic BioPharma, Inc. faces intense competition in the biopharmaceutical industry. Success depends on maintaining a competitive edge through:

• Proprietary Technology: Leveraging unique platforms to develop innovative therapies.
• Clinical Trial Success: Demonstrating superior efficacy and safety compared to existing treatments.
• Strategic Partnerships: Collaborating with key players to expand market reach and development capabilities.

To provide a clearer picture, here's a hypothetical outlook based on potential milestones:

These milestones are speculative and serve only as illustrative examples. Actual timelines and outcomes may vary significantly.

For more insights into the foundational principles guiding Kiromic BioPharma, Inc., explore Mission Statement, Vision, & Core Values of Kiromic BioPharma, Inc. (KRBP).